A Phase II Clinical Study to Investigate Taletrectinib (AB-106) in Treating Patients with ROS1 Fusion Positive Non-Small Cell Lung Cancer (TRUST Phase II study) (pdf)

A Phase II Clinical Study to Investigate Taletrectinib (AB-106) in Treating Patients with ROS1 Fusion Positive Non-Small Cell Lung Cancer (TRUST Phase II study) (pdf) Read More »